Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AdvisorShares Psychedelics ETF (NY:PSIL)

11.25 +0.24 (+2.18%)
Streaming Delayed Price Updated: 11:36 AM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AdvisorShares Psychedelics ETF

< Previous 1 2 3 4 5 Next >
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
Via Benzinga
These 8 Fringe ETF Returns Ranged From +13% To -5% Last Week
If you are interested in any of the cannabis, psychedelic, cryptocurrency, artificial intelligence, 
Via Talk Markets
Psychedelic Stocks Jumped 10% Last Week
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly 
Via Talk Markets
Check Out These 8 Fringe ETFs
If you are bullish on any of the cannabis, psychedelic, cryptocurrency, artificial intelligence (AI), 
Via Talk Markets
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
Via Talk Markets
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Science Conference In Dubai, UAE Hosts Discussion On Psychedelics Research 
Via Benzinga
Major Psychedelic Compound-Based Research & Development Stocks: June Update
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index 
Via Talk Markets
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
Major Investor Commits $30 Million To Psychedelics Funding 
Via Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
ETFs Outperforming The S&P 500, On Average
If you are bullish on any of the cannabis, psychedelic, cryptocurrency, or gold and silver junior miner categories then consider buying these six ETFs. 
Via Talk Markets
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. 
Via Benzinga
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
MDMA Therapy For PTSD Nearing Legalization In U.S. And Worldwide, MAPS Releases Promising Data 
Via Benzinga
"Multi-Bagger" Portfolio Down 13% In March; Still Up Almost 6% YTD
The 
Via Talk Markets
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. 
Via Benzinga
Our Aggressive ETF Portfolio Is Outperforming The S&P 500 By A 2-To-1 Margin
Our Aggressive ETF Portfolio consists of 6 ETFs containing some downtrodden categories: cannabis MSOs and LPs, psychedelic stocks, cryptocurrency futures, and junior gold and silver miners. 
Via Talk Markets
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses 
Via Benzinga
An Aggressive ETF Portfolio For 2023: An Update
If you are bullish on any of the cannabis, psychedelic, cryptocurrency, or gold and silver junior miner categories, take a look at these ETFs. 
Via Talk Markets
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
An Update On The Performance Of The 7 Largest Psychedelic Stocks
The 7 largest psychedelic drug stocks are ranked as to their stock performances since the beginning of March and year-to-date, their likelihood of financial distress, analyst price forecasts and the... 
Via Talk Markets
The "Multi-Bagger" Portfolio: An Update
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 - DOWN 73% vs. 2021 - but perhaps some of them will bounce back with major - dare I say 
Via Talk Markets
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Largest Psychedelic Stocks Down 13% Last Week; Down 20% YTD
This article presents the likelihood of the 7 largest psychedelic drug experiencing Financial Distress within the next 2 years, their average year-end price targets and their stock performances last... 
Via Talk Markets
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.